Air Liquide, FR0000120073

Air Liquide stock faces UK antitrust scrutiny over Vivisol deal

Published on 11/20/2026 at 10:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Air Liquide stock faces a UK competition review over Vivisol's planned purchase of its home-oxygen business. Remedies are due by November 26.

UK review puts Vivisol deal under scrutiny

  • The CMA said the proposed transaction could substantially lessen competition in UK home-oxygen services.
  • Vivisol and Air Liquide have until November 26 to offer remedies before a possible Phase 2 investigation.
  • The transaction concerns assets serving National Health Service patients.
Air Liquide, FR0000120073, Illustration mit AI erstellt.

On Thursday, November 19, 2026, the U.K. Competition and Markets Authority raised competition concerns about Vivisol's proposed acquisition of Air Liquide Healthcare's U.K. home-oxygen business, according to Morningstar, which carried a Dow Jones Newswires report. The transaction would transfer business assets used to supply home-oxygen services to U.K. National Health Service patients.

Dolby Medical Home Respiratory Care, trading as Vivisol, has agreed to acquire the assets from Air Liquide Healthcare. Vivisol is a subsidiary of Italy-listed Sol. The CMA said its initial investigation found that the deal might result in a substantial lessening of competition in the U.K.

Remedies could determine the next step

The parties have until November 26 to offer undertakings addressing the CMA's concerns. If no remedies are offered, or if the proposed measures are judged insufficient, the watchdog said it will refer the transaction for an in-depth Phase 2 investigation.

For Air Liquide, the review adds a regulatory condition to a disposal in its healthcare activities. The immediate issue is not the group's industrial-gases operations but the competitive position of home-oxygen services supplied to NHS patients. The CMA's next decision will determine whether the transaction can proceed with remedies or move into a more detailed investigation.

Air Liquide stock trades ahead of the decision

Air Liquide stock traded at 188.65 euros on Lang & Schwarz at 10:01 CET on Friday, November 20, 2026.

Air Liquide stock

  • Company: Air Liquide
  • ISIN: FR0000120073
  • Trading venue: Lang & Schwarz
  • Quote: 188.65 euros at 10:01 CET on November 20, 2026

The CMA's November 26 deadline is the next stated milestone for investors monitoring the transaction. A remedy offer could allow the deal to advance, while a referral would extend the regulatory process and increase execution uncertainty for the disposal.

In the French market, the CAC 40 provides the relevant broader equity context: Current market reports.

More news and analyses on Air Liquide stock

Disclaimer...
en | FR0000120073 | AIR LIQUIDE | boerse | 70539450 | bgmi